News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
485,843 Results
Type
Article (8016)
Company Profile (142)
Press Release (477954)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166713)
Career Advice (303)
Deals (25738)
Drug Delivery (7)
Drug Development (52797)
Employer Resources (14)
FDA (9749)
Job Trends (8570)
News (238059)
Policy (17881)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (6)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (490)
Accelerated approval (26)
ADA (18)
Adcomms (1)
Allergies (98)
Alliances (33155)
ALS (112)
Alzheimer's disease (985)
Antibody-drug conjugate (ADC) (285)
Approvals (10418)
Artificial intelligence (336)
ASCO (159)
Autoimmune disease (221)
Automation (29)
Bankruptcy (263)
Belgium (1)
Best Places to Work (6958)
BIO (36)
Biologics (9)
BIOSECURE Act (1)
Biosimilars (114)
BioSpace Insights (17)
Biotechnology (90)
Bispecific (1)
Bladder cancer (140)
Brain cancer (31)
Breast cancer (521)
Cancer (3774)
Cardiovascular disease (227)
Career advice (245)
Career pathing (1)
CAR-T (178)
CDC (1)
CDMO (19)
Celiac Disease (1)
Cell therapy (490)
Cervical cancer (35)
Clinical research (48064)
Collaboration (1282)
Commercialization (3)
Compensation (1538)
Complete response letters (34)
COVID-19 (763)
CRISPR (64)
C-suite (807)
Cystic fibrosis (87)
Data (5876)
Denatured (4)
Depression (107)
Dermatology (68)
Diabetes (357)
Diagnostics (4222)
Digital health (39)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (160)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (166)
Earnings (73749)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (88135)
Executive appointments (714)
FDA (12511)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (18)
Frontotemporal dementia (24)
Funding (950)
Gene editing (126)
Generative AI (11)
Gene therapy (335)
GLP-1 (294)
Government (948)
Grass and pollen (2)
Guidances (281)
Healthcare (9368)
Hematology (94)
HIV (55)
Huntington's disease (23)
IgA nephropathy (68)
Immunology and inflammation (108)
Immuno-oncology (61)
Indications (164)
Infectious disease (955)
Inflammatory bowel disease (129)
Inflation Reduction Act (4)
Influenza (85)
Intellectual property (262)
Interviews (41)
IPO (12388)
IRA (2)
Job creations (1968)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Kidney disease (46)
Layoffs (59)
Legal (5195)
Licensing (19)
Liver cancer (45)
Longevity (19)
Lung cancer (547)
Lymphoma (258)
Machine learning (29)
Management (3)
Manufacturing (571)
Marketing (8)
MASH (118)
Medical affairs (2)
Medical device (8682)
Medtech (8841)
Mergers & acquisitions (14411)
Metabolic disorders (730)
mRNA (64)
Multiple sclerosis (107)
NASH (4)
Neurodegenerative disease (228)
Neuropsychiatric disorders (40)
Neuroscience (1879)
NextGen: Class of 2026 (3150)
Non-profit (843)
Obesity (232)
Opinion (10)
Ovarian cancer (161)
Pain (177)
Pancreatic cancer (207)
Parkinson's disease (206)
Partnered (12)
Patents (500)
Patient recruitment (531)
Patient selection (2)
Peanut (32)
People (41367)
Peptides (3)
Pharmaceutical (30)
Pharmacy benefit managers (9)
Phase 1 (15521)
Phase 2 (21463)
Phase 3 (14473)
Pipeline (7733)
Policy (18)
Postmarket research (1570)
Preclinical (6555)
Press Release (34)
Prostate cancer (193)
Psychedelics (7)
Radiopharmaceuticals (195)
Rare diseases (590)
Real estate (3023)
Recruiting (6)
Regenerative medicine (2)
Regulatory (14982)
Reports (23)
Research institute (584)
Resumes & cover letters (45)
Rett syndrome (42)
RNA editing (5)
RSV (48)
Schizophrenia (104)
Series A (165)
Series B (122)
Service/supplier (5)
Sickle cell disease (63)
Spinal muscular atrophy (90)
Sponsored (5)
Startups (2020)
Stomach cancer (3)
Substance use disorders (16)
Supply chain (51)
Vaccines (335)
Venture capital (17)
Weight loss (75)
Women's health (89)
Date
Today (71)
Last 7 days (259)
Last 30 days (1447)
Last 365 days (19089)
2026 (13742)
2025 (19251)
2024 (22989)
2023 (26530)
2022 (34589)
2021 (37168)
2020 (33447)
2019 (23257)
2018 (17469)
2017 (18765)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18135)
2012 (20221)
2011 (20426)
2010 (20332)
Location
Africa (229)
Alabama (78)
Alaska (2)
Arizona (311)
Arkansas (11)
Asia (17972)
Australia (2109)
California (12372)
Canada (3248)
China (548)
Colorado (499)
Connecticut (427)
Delaware (215)
Europe (24692)
Florida (1862)
Georgia (393)
Hawaii (3)
Idaho (46)
Illinois (730)
India (52)
Indiana (324)
Iowa (16)
Japan (428)
Kansas (103)
Kentucky (32)
Louisiana (27)
Maine (26)
Maryland (1232)
Massachusetts (8118)
Michigan (315)
Minnesota (573)
Mississippi (4)
Missouri (82)
Montana (20)
Nebraska (11)
Nevada (123)
New Hampshire (60)
New Jersey (2707)
New Mexico (12)
New York (2903)
North Carolina (1318)
North Dakota (4)
Northern California (6221)
Ohio (296)
Oklahoma (14)
Oregon (16)
Pennsylvania (2300)
Puerto Rico (21)
Rhode Island (30)
South America (406)
South Carolina (78)
South Dakota (1)
Southern California (5152)
Tennessee (125)
Texas (2015)
United States (40123)
Utah (375)
Vermont (1)
Virginia (159)
Washington D.C. (38)
Washington State (957)
West Virginia (1)
Wisconsin (75)
Wyoming (1)
485,843 Results for "stemcyte inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVID
January 27, 2026
·
2 min read
Press Releases
U.S. FDA Approves StemCyte Biologics License Application for REGENECYTE™ Cord Blood Cell Therapy Product
November 22, 2024
·
2 min read
Press Releases
StemCyte’s HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment
October 3, 2024
·
2 min read
Press Releases
StemCyte Announces Successful Phase IIa Clinical Trial Results for HPC, Cord Blood in Treating Post-COVID Syndrome: 85% of Patients Experience Complete Relief from Fatigue Symptoms
December 19, 2024
·
6 min read
Biotech Beach
StemCyte Announces Breakthrough Allogeneic Cell Therapy Technology
StemCyte, Inc. and Professor Hu Che-Ming of the Academia Sinica Taiwan jointly developed the world’s first initiative to use allogeneic dendritic cells to activate the immune system for the treatment of diseases.
August 4, 2021
·
2 min read
Drug Development
StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood
Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company’s clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB).
January 26, 2022
·
3 min read
Drug Development
StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy
Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy.
August 29, 2022
·
3 min read
Business
StemCyte Inc. Extends Umbilical Cord Blood Collection Operation at Three Hospital Collection Sites in Southern California
California-based StemCyte is pleased to announce expanded hours for umbilical cord blood collection at three hospital sites in Southern California
May 11, 2021
·
3 min read
Policy
StemCyte, a leading regenerative cell therapy company, has submitted its application for a biologics license (BLA) for its allogeneic umbilical cord hematopoietic progenitor cell product “HPC-Cord Blood”, to the US FDA
The BLA for the “HPC-Cord Blood” product, was submitted to FDA on January 7th, 2022, and StemCyte was officially notified on March 8th, 2022, that the submission was acceptable to enter the biologics license quality review process.
March 22, 2022
·
2 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
1 of 48,585
Next
